Clinical Trial Update: Evaluating the Pharmacokinetics of 400 mg Oral Dose of Raltegravir in HIV-Infected Pre-Menopausal Women

View source ↗

Summary

A completed clinical trial evaluating the pharmacokinetics of a 400 mg oral dose of raltegravir in HIV-infected pre-menopausal women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Isentress (Raltegravir)

Snippet

Sponsor: Kristine Patterson, MD | Conditions: HIV Infections | Status: COMPLETED